In reference to the articles reported in the European press on 14 and 15 April 2017, Aspen Pharmacare Holdings Limited (“Aspen”) has the following comments: Aspen has clearly demonstrated its commitment to providing quality medicines affordably over many years. The supply of the oncology products in question is no exception. Aspen’s status as a responsible… Continue reading Statement in response to press reports of 14 and 15 April 2017
Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform to be released on 4 March 2024.
